Alzheimer's disease: The strength of association of costs with different measures of disease severity

作者: J. Mauskopf , J. Racketa , E. Sherrill

DOI: 10.1007/S12603-010-0312-6

关键词:

摘要: Objective: To identify Alzheimer's disease (AD) severity measures for use in cost-effectiveness models that effectively capture the impact of AD on costs. Methods: A review literature and data abstraction from papers present 1) mean costs (direct, indirect, or total) by severity, defined using measure cognition, functional status, behavior; and/or 2) results regression analyses estimate strength association between severity. Results: All reviewed showed total increase with regardless severity-measurement method. The relative difference patients severe compared to those moderate disease, mild was fairly consistent across studies, suggesting any disease-severity may be used broadly categorize cost. However, when analysis included multiple measures, independent associations were noted different measures. Cognitive status consistently associated direct costs, whereas behavioral indirect caregiver hours. Conclusions: Either multidimensional a single measure, behavior are needed models.

参考文章(53)
Neumann Pj, Leon J, The cost of Alzheimer's disease in managed care: a cross-sectional study. The American Journal of Managed Care. ,vol. 5, pp. 867- ,(1999)
Jordi Peña-Casanova, Joan Rovira, Mercé Boada, Félix Bermejo, Warren M. Hart, Cristina Espinosa, Francisco Guillén, Coste de los recursos sanitarios de los pacientes en régimen ambulatorio diagnosticados de enfermedad de Alzheimer en España Medicina Clinica. ,vol. 113, pp. 690- 695 ,(1999)
Jaime Caro, , Denis Getsios, Kristen Migliaccio-Walle, Jack Ishak, Wissam El-Hadi, Rational choice of cholinesterase inhibitor for the treatment of Alzheimer's disease in Canada: a comparative economic analysis BMC Geriatrics. ,vol. 3, pp. 6- 6 ,(2003) , 10.1186/1471-2318-3-6
Cl??ment Fran??ois, Harri Sintonen, Raimo Sulkava, Beno??t Rive, Cost effectiveness of memantine in moderately severe to severe Alzheimer's disease : a markov model in Finland. Clinical Drug Investigation. ,vol. 24, pp. 373- 384 ,(2004) , 10.2165/00044011-200424070-00001
Jacqueline S Birks, Cholinesterase inhibitors for Alzheimer's disease Cochrane Database of Systematic Reviews. ,(2006) , 10.1002/14651858.CD005593
Dorothy P. Rice, Patrick J. Fox, Wendy Max, Pamela A. Webber, Walter W. Hauck, David A. Lindeman, Ernestine Segura, The economic burden of Alzheimer's disease care Health Affairs. ,vol. 12, pp. 164- 176 ,(1993) , 10.1377/HLTHAFF.12.2.164
Carolyn W Zhu, Mary Sano, Economic considerations in the management of Alzheimer's disease. Clinical Interventions in Aging. ,vol. 1, pp. 143- 154 ,(2006) , 10.2147/CIIA.2006.1.2.143
Linus Jönsson, Maria Eriksdotter Jönhagen, Lena Kilander, Hilkka Soininen, Merja Hallikainen, Gunhild Waldemar, Harald Nygaard, Niels Andreasen, Bengt Winblad, Anders Wimo, Determinants of costs of care for patients with Alzheimer's disease. International Journal of Geriatric Psychiatry. ,vol. 21, pp. 449- 459 ,(2006) , 10.1002/GPS.1489
Bernie J. O'Brien, Ron Goeree, Margaret Hux, Michael Iskedjian, Gordon Blackhouse, Michelle Gagnon, Serge Gauthier, Economic Evaluation of Donepezil for the Treatment of Alzheimer's Disease in Canada Journal of the American Geriatrics Society. ,vol. 47, pp. 570- 578 ,(1999) , 10.1111/J.1532-5415.1999.TB02572.X